期刊文献+

静脉用免疫球蛋白对脓毒症患儿免疫状态及转归的影响

Effect of intravenous immunoglobulin on immunity and outcome for sepsis in children
原文传递
导出
摘要 目的探讨静脉用免疫球蛋白(intravenous immunoglobulin,IVIG)对脓毒症患儿免疫状态以及转归的影响。方法2008年8月至2010年4月入住我院儿童重症医学科符合脓毒症诊断的患儿84例,分为对照组(48例)和治疗组(36例),治疗组一次性输注IVIG1g/kg,分别于用药前(0h)及用药后24h、72h和5d抽取两组患儿外周静脉血,在流式细胞仪上进行免疫细胞(CD3+、CD4+、CD56+、CD29+、CD8+)计数,采用ELISA法检测细胞因子[肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-10、IL—17]水平并计算TNF-α/IL-10。比较两组患儿各时间点免疫细胞计数、细胞因子水平以及TNF-α/IL-10变化,并观察比较两组患儿28d病死率。结果治疗组患儿CD3+、CD4+、CD56+、CD19+细胞计数,TNF-α、IL—17以及TNF-a/lL—10在应用IVIG后24h、72h、5d均明显低于对照组(P〈0.05),并且呈进行性下降趋势;而IL-10则明显增高(P〈0.05),呈上升趋势;CD8+细胞计数无明显变化。治疗组28d死亡10例(27.7%,10/36),对照组死亡8例(16.6%,8/48),两组比较差别无统计学意义(X2=1.50,P=0.169,OR=1.92,95%CI:0.671~5.510)。结论IVIG可使脓毒症患儿机体处于免疫麻痹状态,并不能提高存活率。 Objective To explore the effect of intravenous immunoglobulin (IVIG) on immunity and outcome for sepsis in children. Methods Eighty-four children who met the diagnosis of sepsis were included in study and divided into treatment group (36 cases ) and control group (48 cases). The patients in teatment group were administered IVIG with the dose of 1 g/kg. Peripheral venous blood samples of patients in bαh groups were collected before (0 h) ,24 h,72 h and 5 d after administration to detect the numbers of immunocyte including CD3 + ,CD4 + ,CD56 + ,CD19 + ,CD8 + cells by flow cytometry and the levels of cytokines including tumor necrosis factor (TNF)-ct, interleukin (IL)-10, IL-17 by enzyme linked immunosorbent assay. The numbers of immunocyte and levels of cytokines and TNF-α/IL-10 were compared and the mortality at 28 days was assessed between two groups. Results The numbers of CD3 + , CD4 + , CD56 + , CD19 + cells and the levels of TNF-α, IL-17 and TNF-oflL-10 of patients in teatment group were significantly decreased than those in control group at 24 h,72 h and 5 d afte administration (P 〈0. 05) and showed downtrend. However, the level of IL-10 increased significantly ( P 〈 0. 05 ) and showed uptrend in treatment group. The number of CD8 + cells had no change. No difference of mortality was observed between two groups (27. 7%, 10/36 vs16.6% ,8/48,X2 = 1.50,P =0. 169,0R = 1.92,95% CI:0. 671 +5.510).Conclusion IVIGcan suppress the immunity of children with sepsis and has no survival benefit.
出处 《中国小儿急救医学》 CAS 2011年第6期497-499,共3页 Chinese Pediatric Emergency Medicine
关键词 脓毒症 静脉用免疫球蛋白 免疫状态 儿童 Sepsis Intravenous immunoglobulin Immunity Children
  • 相关文献

参考文献19

  • 1Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med, 2010,38(5) :1276-1283.
  • 2Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008 : a systematic analysis. Lancet ,2010,375 (9730) : 1969-1987.
  • 3Wynn J, Comell TT, Wong HR, et al. The host response to sep- sis and developmental impact. Pediatrics,2010,125 (5) : 1031- 1041.
  • 4Kreymann KG, de Heer G, Nierhaus A, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med,2007,35 ( 12 ) :2677-2685.
  • 5樊寻梅.儿科感染性休克(脓毒性休克)诊疗推荐方案[J].中华儿科杂志,2006,44(8):596-598. 被引量:205
  • 6Osuchowski MF,Welch K, Siddiqui J, et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/ CARS continuum in sepsis and predict mortality. J Immunol, 2006,177 ( 3 ) : 1967-1974.
  • 7付丹,李成荣,何颜霞,王国兵,祖莹,杨军,黄雀兰,苏颖.婴幼儿脓毒症不同免疫状态细胞因子变化探讨[J].中国小儿急救医学,2009,16(5):438-440. 被引量:17
  • 8Berlot G,Bacer B, Piva M, et al. Immunoglobulins in sepsis. Adv Sepsis,2007,6(2) :41-46.
  • 9Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit Care Med,2007,35 ( 12 ) :2686-2692.
  • 10Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med,2007,35 ( 12 ) :2693-2701.

二级参考文献30

  • 1樊寻梅.儿科感染性休克(脓毒性休克)诊疗推荐方案[J].中华儿科杂志,2006,44(8):596-598. 被引量:205
  • 2中华医学会儿科学会急救学组.小儿危重病例评分法(草案)[J].中华儿科杂志,1995,33(6):371-371.
  • 3Lekkou A, Karakantza M, Mouzaki A, et al. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol,2004,11 ( 1 ) :161-167.
  • 4Osuchowski MF, Welch K, Siddiqui J. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol,2006,177 (3) : 1967-1974.
  • 5Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med, 1996,24(7 ) : 1125-1128.
  • 6Volk liD, Reinke P, Krausch D. Monocle deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Me.A, 1996,22 ( Suppl 4) : S474-481.
  • 7Monneret G, Lepape N, Voirin J, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med,2006,32 (8) : 1175-1183.
  • 8Venet F, Tissot S, Debard AL. et al. Decreased monocyte human leukocyte antigen-DR expression after severe bum injury:Correlation with severity and secondary septic shock. Crit Care Med, 2007,35(8) :1910-1917.
  • 9Yoshida S. Monocyte HLA-DR expression as predictors of clinical outcome for patients with sepsis. Nippon Rinsho, 2004,62 (12) :2281-2284.
  • 10Abe R,Hirasawa H,Oda S, et al. Up-Regulation of Interleukin-10 mRNA Expression in Peripheral Leukocytes Predicts Poor Outcome and Diminished Human Leukocyte Antigen-DR Expression on Monocytes in Septic Patients. J Surg Res,2008,147 (1) :1-8.

共引文献222

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部